The Virginia Biosciences Health Research Corporation, known as Virginia Catalyst, today announced that it has awarded a $400,000 grant to a collaborative bioscience commercialization project including a team from Virginia Commonwealth University, Eastern Virginia Medical School and ReAlta Life Sciences, LLC. This grant, which includes matching funding of $400,000 provided by ReAlta, is intended to establish the efficacy of Peptide Inhibitor of Complement C1 (PIC1) in decreasing brain injury in an animal model of neonatal Hypoxic-Ischemic Encephalopathy (HIE), as well as establish the long-term improvement in neurological outcomes after PIC1 treatment in an animal model of neonatal HIE.
Read the full press release here.
Your comment will be posted after it is approved.
Leave a Reply.